NO20073039L - Kontrastmidler - Google Patents

Kontrastmidler

Info

Publication number
NO20073039L
NO20073039L NO20073039A NO20073039A NO20073039L NO 20073039 L NO20073039 L NO 20073039L NO 20073039 A NO20073039 A NO 20073039A NO 20073039 A NO20073039 A NO 20073039A NO 20073039 L NO20073039 L NO 20073039L
Authority
NO
Norway
Prior art keywords
contrast agents
biomodifier
areas
human
general formula
Prior art date
Application number
NO20073039A
Other languages
English (en)
Inventor
Dagfinn Lovhaug
Morten Eriksen
Hege B Fjerdingstad
Andrew Healey
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Priority to NO20073039A priority Critical patent/NO20073039L/no
Publication of NO20073039L publication Critical patent/NO20073039L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Steroid Compounds (AREA)

Abstract

Kontrastmiddel av generell formel (I): Z1-L-V-Z2 (I) der minst en av Z1 og Z2 er til stede og er like eller forskjellige reportergrupper som kan detekteres ved avbilding av den levende menneske- eller dyrekroppen, V er en målrettet gruppe med bindingsaffinitet for områder der det dannes kollagen, L er en kovalent binding, en biologisk modifiserende enhet eller en linkergruppe.
NO20073039A 2004-11-22 2007-06-14 Kontrastmidler NO20073039L (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20073039A NO20073039L (no) 2004-11-22 2007-06-14 Kontrastmidler

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NO20045081 2004-11-22
PCT/NO2005/000435 WO2006054904A2 (en) 2004-11-22 2005-11-21 Contrast agents to target extracellular matrix
NO20073039A NO20073039L (no) 2004-11-22 2007-06-14 Kontrastmidler

Publications (1)

Publication Number Publication Date
NO20073039L true NO20073039L (no) 2007-08-16

Family

ID=36182407

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073039A NO20073039L (no) 2004-11-22 2007-06-14 Kontrastmidler

Country Status (17)

Country Link
US (1) US8182790B2 (no)
EP (2) EP2243496A3 (no)
JP (2) JP5116480B2 (no)
KR (1) KR20070091609A (no)
CN (1) CN101107016B (no)
AT (1) ATE494913T1 (no)
AU (1) AU2005307195A1 (no)
BR (1) BRPI0518328A2 (no)
CA (1) CA2586621A1 (no)
DE (1) DE602005025911D1 (no)
ES (1) ES2358745T3 (no)
IL (1) IL182898A0 (no)
MX (1) MX2007006050A (no)
NO (1) NO20073039L (no)
RU (1) RU2007118385A (no)
WO (1) WO2006054904A2 (no)
ZA (1) ZA200705043B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
JP2010502585A (ja) * 2006-08-28 2010-01-28 ジーイー・ヘルスケア・リミテッド ６８Ｇａ標識ペプチド系放射性医薬品
JP2008266194A (ja) * 2007-04-19 2008-11-06 Hiroshi Tanaka 分子プローブの原料として有用な新規有機化合物
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
US8466258B2 (en) 2007-12-13 2013-06-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Polypeptides, cyclic polypeptides and pharmaceutical comprising thereof for non invasive specific imaging of fibrosis
DK2244741T3 (en) 2008-01-18 2015-05-26 Visen Medical Inc Fluorescent imaging agents
WO2009140408A2 (en) 2008-05-13 2009-11-19 University Of Kansas Metal abstraction peptide (map) tag and associated methods
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
KR100991716B1 (ko) * 2009-10-22 2010-11-04 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치
CN102504603B (zh) * 2011-10-20 2014-01-29 中国海洋大学 一种多聚物与生物染色剂的偶合物及其制备方法和用途
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
US20170050989A1 (en) * 2013-12-03 2017-02-23 The General Hospital Corporation Molecular Imaging Probes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4615876A (en) * 1983-04-25 1986-10-07 Curators Of The University Of Missouri Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US6048982A (en) 1986-04-18 2000-04-11 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
ATE145337T1 (de) 1988-05-02 1996-12-15 Phanos Tech Inc Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
GB8903022D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
CA2124329C (en) 1991-11-27 2008-11-18 Gregory A. Kopia Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
KR20000052830A (ko) 1996-10-28 2000-08-25 조오지 디빈센조, 토브 아스 헬지, 에바 요한손 진단/치료제 또는 그와 관련된 개선
WO1998018496A2 (en) 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
EP1011736A2 (en) * 1997-01-29 2000-06-28 Nycomed Imaging As Polymers
WO1999005221A1 (en) 1997-07-28 1999-02-04 Nycomed Amersham Plc Cyanine dyes
US5942637A (en) 1998-03-30 1999-08-24 North Dakota State University Research Foundation Compounds containing tetradecachlorocyclohexasilane dianion
US6852318B1 (en) 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
EP2327451B1 (en) * 1998-05-08 2013-10-23 The Regents of the University of California Method for detecting and inhibiting angiogenesis
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
US6230777B1 (en) 1999-02-04 2001-05-15 Midmac Systems, Inc. Filter forming and joining apparatus
ES2244607T3 (es) * 2000-04-12 2005-12-16 Amersham Health As Derivados peptidicos de union a integrina.
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
WO2002055111A2 (en) * 2000-11-27 2002-07-18 Bristol Myers Squibb Medical I Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
GB0116815D0 (en) 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
HU230901B1 (hu) * 2001-07-10 2019-01-28 Ge Healthcare Limited Peptidalapú vegyületek és ezeket tartalmazó gyógyszerkészítmények
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
EP1589986B1 (en) 2002-06-17 2008-10-29 Cartela R & D AB Methods and uses of the integrin alpha 10 chain, for diagnosing and detecting atherosclerosis plaque formation in vitro
US7063158B2 (en) 2003-06-16 2006-06-20 Deepwater Technologies, Inc. Bottom tensioned offshore oil well production riser
NO20033115D0 (no) * 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
WO2005019247A2 (en) 2003-08-15 2005-03-03 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
US7431914B2 (en) * 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
WO2005084715A2 (en) * 2004-03-04 2005-09-15 Ge Healthcare As Conjugates of angiotensin peptidic analogues and chelating agents for diagnosis and therapy
KR20070029200A (ko) * 2004-06-16 2007-03-13 지이 헬스케어 에이에스 펩티드계 화합물
BRPI0512209A (pt) * 2004-06-16 2008-02-19 Ge Healthcare As composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens de um corpo humano ou de animal por formação de imagem óptica, e de monitoração do efeito de tratamento de um corpo humano ou de animal com uma droga para combater uma condição associada com angiogênese

Also Published As

Publication number Publication date
RU2007118385A (ru) 2008-12-27
AU2005307195A1 (en) 2006-05-26
IL182898A0 (en) 2007-08-19
EP1814598B1 (en) 2011-01-12
US20090208412A1 (en) 2009-08-20
WO2006054904A2 (en) 2006-05-26
ZA200705043B (en) 2008-09-25
ATE494913T1 (de) 2011-01-15
ES2358745T3 (es) 2011-05-13
EP2243496A3 (en) 2012-12-26
CA2586621A1 (en) 2006-05-26
JP5116480B2 (ja) 2013-01-09
CN101107016A (zh) 2008-01-16
BRPI0518328A2 (pt) 2008-11-11
DE602005025911D1 (de) 2011-02-24
CN101107016B (zh) 2011-11-16
US8182790B2 (en) 2012-05-22
EP2243496A2 (en) 2010-10-27
EP1814598A2 (en) 2007-08-08
JP2012207027A (ja) 2012-10-25
MX2007006050A (es) 2007-11-14
KR20070091609A (ko) 2007-09-11
WO2006054904A3 (en) 2007-04-05
JP2008520658A (ja) 2008-06-19

Similar Documents

Publication Publication Date Title
NO20073039L (no) Kontrastmidler
ECSP066311A (es) Derivados de la piperazina y su uso como agentes terapéuticos
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
DE60042522D1 (de) Cyanin- oder indocyaninefarbstoffe biokonjugate für biomedische anwendungen
ATE426414T1 (de) Vitamin-mitomycin-konjugate
CY1110505T1 (el) Ανθρωπινα αντισωματα dr4 και χρησεις αυτων
EP2269610A3 (en) Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
DE69934337D1 (de) Konjugate zur Behandlung von Entzündungskrankheiten und von assozierter Gewebeschädigung
CY1109722T1 (el) Ενδιαμεσες ενωσεις για την παρασκευη της trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,73oxepino[4,5-c]pyrrole
DE60234057D1 (de) Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
WO1998018497A3 (en) Contrast agents
ATE530168T1 (de) Magnetische nanoteilchen-zusammensetzungen und ihre verwendungen
ATE314097T1 (de) Kontrastmittel
CY1107609T1 (el) Απεικoνιση, διaγνωση και θεραπεiα ασθeνειας
SG158919A1 (en) Constructs binding to phosphatidylserine and their use in disease treatment
NO20052925D0 (no) Vannloselige anioniske bakterieklorofyllderivater og deres anvendelse
ATE429450T1 (de) Chimärische dr4 antikörper und ihre verwendung
HUP0400904A2 (en) Use of genes as molecular markers in diagnosis of schizophrenia and diagnostic kit for the same
BRPI0418552A (pt) compostos de alvejamento de piperidinila que seletivamente ligam-se à integrinas
ATE547009T1 (de) Zusammensetzungen und verfahren zur förderung von körperfettverlust
DE50207866D1 (de) Verwendung löslicher cytokeratin-1-fragmente in diagnostik
ATE425770T1 (de) Kontrastmittel
EP1611151A4 (en) STQ Peptides
WO2005049095A3 (en) Contrast agent imaging angiotensin ii receptors
ATE306283T1 (de) Biotin-derivate und ihre konjugaten mit chelatierungsmitteln

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application